[ad_1]
A start-up in London has created a blockchain-based cancer screening system that claims to deliver results in minutes.
Lancor Scientific, founded in the early 2018, created a token & # 39; Medici & # 39; – a form of cryptocurrency – that can be used to access its blockchain platform.
Through this platform, patients will be able to book, review and pay for their cancer screening tests.
According to the company, its Tumor Trace device uses opto-magnetic imaging spectroscopy to identify changes in tissue that occur when cancer develops.
It is said that its detector is able to detect signs of cancer with a 90% accuracy within two minutes.
Users of the screening service access the portal via their smartphone and register an account on the web portal. They can pay in various currencies, including cryptocurrencies.
The user will then make a projection at a clinic registered at the platform, verifying his identity through his smartphone.
When the report has been created, it will be shared with the patient. According to Lancor, the report is stored on a separate private blockchain to ensure that patient data is secure.
Aamir Butt, CEO of the start-up, said: "Lancor Scientific aims to make cancer screening an early diagnosis accessible to everyone.
"The use of the Tumor Trace device combined with our blockchain oncology registry will see this potential become a reality, especially in the countries that need it most".
Speaking to the standard, he added that he hopes to bring the technology into the national health system once the accuracy of the mechanism has been improved.
"The plan is to work with the NHS. We are thinking of multiple diagnostic centers where we could see technology having a home," he said.
Butt could not rule out that the cost of screening could fall on the patient, but added that the decision would be taken by the governments of each country where it was launched.
At the moment, he would like to see the technology used in the NHS within two years, and privately available at some point in 2019.
Although the technology is currently being tested in Austria, Cancer Research UK has warned that all new screening systems used in the UK must be studied to ensure that they are safe.
Emma Shields, of CRUK, said: "The UK has three national cancer screening programs for specific age groups, which aim to diagnose intestinal, breast and cervical tumors before symptoms develop.
"These programs are based on evidence examined by the UK National Selection Committee, which also considers how practical and appropriate each program is.
"Any potential screening test must be carefully studied to make sure the benefits outweigh the damage."
